Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Primary immune thrombocytopenia ITP is a condition where the immune system mistakenly destroys platelets, leading to a low platelet count that increases the risk of bruising and bleeding. This Phase 3 study aims to evaluate the long-term safety, tolerability, and effectiveness of mezagitamab, a subcutaneous injection, in adults with chronic primary ITP. It also studies how the body processes mezagitamab over an extended period. Eligible participants who completed previous mezagitamab studies TAK-079-3002 or TAK-079-1004 may join this continuation trial. Those from TAK-079-1004 must have shown a platelet response previously. Participants receive mezagitamab treatment on demand based on defined dosing criteria and the clinical judgment of the investigator, with treatment courses possibly repeated as needed. During the trial, participants visit the study clinic multiple times for assessments including monitoring treatment-emergent adverse events, platelet response duration, use of rescue therapy, and drug levels in the blood. The study lasts up to about 108 weeks, with evaluations of safety, effectiveness, immunogenicity, and dosing patterns throughout this period.
Actively Recruiting
Researchers are studying chronic primary immune thrombocytopenia ITP, a condition where the immune system mistakenly destroys platelets, leading to easier bruising and bleeding due to low platelet counts. The trial aims to evaluate whether mezagitamab, given as a subcutaneous injection, can maintain stable platelet levels in adults with ITP compared to a placebo. This Phase 3 study is randomized, double-blind, and placebo-controlled to thoroughly assess mezagitamabs effects. Participants will receive either mezagitamab or a matching placebo injection once weekly. The dosing schedule includes 8 weeks of weekly injections, followed by an 8-week break, and then another 8 weeks of weekly injections, totaling up to 6 months of treatment. Those who complete this study or do not respond by week 16 may have the option to join a continuation study to receive open-label mezagitamab if eligible. During the study, participants will visit the clinic multiple times for assessments. Researchers will monitor platelet counts regularly and evaluate responses using measures such as the percentage of participants with durable platelet response up to week 24. Additional assessments include symptom questionnaires, fatigue scores, bleeding events, and monitoring of mezagitamab levels and antibodies. The study also observes safety and treatment effects through week 24 and beyond as needed.